Penny stocks are a viable way to see some big returns at a time of market uncertainty. That’s because small-cap penny stocks can see big gains very quickly, while larger stocks tend to be slower moving.
Here are 7 penny stocks in the health care sector each trading at under $2 a share as of this writing. Although these health care stocks may not be industry giants, they have shown long-term return potential for investors with strong year to date market performances.
Antares Pharma Inc. (AIS)
Market Cap: $133.68 million
Antares Pharma, Inc. (AMEX: AIS) is a pharmaceutical company that focuses on self-injection pharmaceutical products and technologies and gel-based products. This small cap pharmaceutical company saw its revenue increase 57% for the first six months of 2010 compared to the same period in 2009. Another positive sign from AIS shares is the +64.58% the stock has gained from its value this time last summer.
Arrowhead Research Corp. (ARWR)
Market Cap: $68.09 million
Arrowhead Research Corporation (NASDAQ: ARWR) is a development stage nanotechnology company focused on the electronics and biotech industries. The California-based company has managed to outperform EPS estimates for three consecutive quarters and shares have improved from a weak start in 2010, with ARWR up +77% since mid-March of this year.
CombinatoRx Inc. (CRXX)
Market Cap: $121.53 million
CombinatoRx, Incorporated (NASDAQ: CRXX) is a biopharmaceutical company engaged in developing drug candidates with a focus on the treatment of pain and inflammation. Year to date, CRXX shares have surprised investors with an upward trend that eclipses the unimpressive broader market performances. Since the start of 2010, shares have gained +64.46%.
Cyclacel Pharmaceuticals (CYCC)
Market Cap: $57.64
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. With shares up nearly +50% since January, CYCC could end up being a bargain at its current price.
Inhibitex Inc. (INHX)
Market Cap: $93.31 million
Inhibitex, Inc. (NASDAQ: INHX) is a biopharmaceutical company focused on the development of differentiated anti-infective products to prevent and treat serious infections. This small cap pharma stock is showing some good growth potential with year to date performance at +68.48%. In addition to shares surging this summer, prospective investors should note that INHX has beat earnings estimates for three of the past four quarters.
Rexahn Pharmaceuticals (RNN)
Market Cap: $98.99 million
Rexahn Pharmaceuticals, Inc. (AMEX: RNN) is a clinical stage biopharmaceutical company developing and seeking to deliver cures for cancer and disorders of the central nervous system in patients. Rexahn’s three clinical stage drug candidates are Archexin, Serdaxin, and Zoraxel. With RNN stock up +75% since the start of the year, shareholders may be finding this Rockville, Md.-based company as the cure for their market ills.
YM Bio Sciences Inc. (YMI)
Market Cap: $101.98 million
YM BioSciences Inc. (AMEX: YMI) is a biopharmaceutical company engaged in the development of products primarily for the treatment of patients with cancer. The Canadian company’s portfolio of products in active clinical development includes one anti-cancer agent targeting more than 10 different tumors and/or stages of cancer, and an inhalation-delivery approach to treat acute pain, including cancer pain. YMI stocks has had some ups and downs over recent months but overall growth looks positive, with shares more than +40% ahead of where they were at this time last August.
As of this writing, Louis Navellier did not own a position in any of the stocks owned here.
The One ETF to Own Now. Louis Navellier’s new profit guide reveals the hottest ETF to buy now, plus details his breakthrough new strategy designed to help you lock in short-term gains from ETFs in sectors just heating up, and then when those sectors are on fire, grab money-doubling profits from the fastest-moving individual stocks. Get your FREE copy here!
